Genexine’s long-acting growth hormone meets Phase 3 primary endpoint

Phase 3 clinical trial in China meets primary endpoint On track to file BLA in China in 2024

Aug 30, 2023Genexine

Genexine abstract on GX-188E and GX-I7 triple combination therapy in HNSCC is released at 2023 ASCO Annual Meeting

Triple combination using Genexine’s DNA vaccine GX-188E, its long-acting Interleukin-7 GX-I7 and Keytruda showed a major pathological response rate of 63.6% in a phase 2 trial, satisfying primary evaluation criteria

May 26, 2023Genexine

Genexine’s long-acting anemia treatment GX-E4 phase 3 clinical trial interim result is presented at WCN2023, confirmed non-inferiority compared to Mircera.

confirmed non-inferiority compared to Mircera

Apr 11, 2023Genexine

Genexine Receives Fast Track Designation from Korean Health Authority (MFDS) for its promising DNA vaccine for advanced cervical cancer

Jan 19, 2023Genexine

Genexine to present final Phase 2 clinical data on its cervical cancer program showing a 35.0% overall response rate and provide a corporate overview during JP Morgan conference

Jan 9, 2023Genexine